Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform.

Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids. The screening of the antitumor properties of cannabinoids on cancer cell lines produces data on groups of patients, while the primary biopsy samples provide us insights on the individual level and may better predict the clinical outcome and improve our preclinical development of proprietary antitumor compounds."

Watch a Video introduction to Cannabics' Lab: https://www.youtube.com/embed/mte263r7nFA

About Cannabics Pharmaceuticals 

Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.